ライフサイエンスコーパス: PDR

1 PDR prevalence in ARV-naive women 18-24 years old was 21

2 PDR prevalence was 9.5% (109/1148) and 12.8% (147/1148)

3 PDR prevalence was calculated by demographics and codon,

4 PDR prevalences (95% confidence interval [CI]) in 815 AR

5 PDR was defined as >/=2% mutant frequency in a participa

6 ent through PINK-1 (PTEN-induced kinase-1)-, PDR-1 (Parkinson's disease-related-1; parkin)-, or DCT-1

7 and between pound 461 and pound 1189 per 100 PDR visits.

8 ti-VEGF treatments were administered to 3685 PDR eyes.

9 ep progression: HR, 1.30; 95% CI, 1.00-1.68; PDR: HR, 1.38; 95% CI, 1.00-1.90).

10 diagnosis (NPDR HR, 0.63; 95% CI, 0.57-0.69; PDR HR, 0.45; 95% CI, 0.37-0.54; and DME HR, 0.39; 95% C

11 t, only abrupt structural violations evoke a PDR.

12 diabetes with a clinical diagnosis of active PDR in any or both eyes, who had long term follow-up for

13 ar age decrease was associated with adjusted PDR prevalence ratio 1.20 (95% CI, 1.06-1.36; P = .004).

14 ate NPDR in 23.9%, severe NPDR in 40.1%, and PDR with 24.8%.

15 (mean = 129), severe NPDR (mean = 203), and PDR (mean = 254); P<5x10(-7)] were strongly associated w

16 diabetes, the prevalence of DME was 4.6% and PDR, 7.4%.

17 ogression (HR, 1.35; 95% CI, 1.05-1.73), and PDR (HR, 1.40; 95% CI, 1.02-1.92) compared with emmetrop

18 ean = 1.20%, severe NPDR (mean = 2.75%), and PDR (mean = 5.84%); P<2x10(-16)], panretinal ischemic in

19 an = 1.37%), severe NPDR (mean = 2.80%), and PDR (mean = 9.53%); P<2x10(-16)], and panretinal microan

20 ects of therapy in patients with wet AMD and PDR.

21 widely used in the treatment of wet-AMD and PDR.

22 association of severe stages of DR (DME and PDR) with incident CVD in patients with type 2 diabetes.

23 of patients, factors associated with DR and PDR were identified and support ongoing efforts to scree

24 in the NPDR (2.0/mm; 95% CI, 1.4-2.7/mm) and PDR stage (1.4/mm; 95% CI, 0.9-2.1/mm) versus in eyes wi

25 to 26.4% among anti-VEGF groups for NPDR and PDR eyes, respectively.

26 The NPDR and PDR groups demonstrated progressively decreasing PCD.

27 the decrease in PCD that follows in NPDR and PDR results largely from an incremental loss of capillar

28 V was lower in NDR than NPDR and PDR subjects (P </= 0.02).

29 tor for 2-step and 3-step DR progression and PDR.

30 In the presence of PVR and PDR, the majority of cytokines are upregulated; thus, th

31 st infections specifically caused by XDR and PDR Gram-negative bacteria.

32 hips between time to treatment (days between PDR diagnosis and PRP) and medical comorbidities (corona

33 nd a previously uncharacterized link between PDR and cell cycle regulation in yeast.

34 e we report how this outcome was impacted by PDR, defined by the World Health Organization (WHO) muta

35 Dual-class PDR to a mainly tenofovir/emtricitabine/efavirenz regime

36 Time from randomization to a composite PDR-worsening outcome defined as the first occurrence of

37 We determined PDR prevalence and correlates in a Kenyan cohort.

38 4.80, and 28.19 times more likely to develop PDR, respectively.

39 ly increased hazard ratio (HR) of developing PDR (HR 1.77, 95% confidence interval [CI] 1.25-2.49, P

40 In patients with diagnosed PDR, a delay in PRP treatment beyond 31 days was associa

41 Phasic pupil dilations (PDR) were monitored to assess Norepinephrine.

42 yeast Saccharomyces cerevisiae Using diverse PDR inducers and the homozygous diploid deletion collect

43 (IRRs) were estimated for patients with DME, PDR, and vision-threatening DR, compared with persons wi

44 n-proliferative DR (NPDR), proliferative DR (PDR) and DME.

45 R) group (n = 48); and the proliferative DR (PDR) group (n = 41).

46 32.4%; severe NPDR, 17.6%; proliferative DR (PDR), 19.1%; and high-risk PDR, 4.4%; with PPL present i

47 p progression, presence of proliferative DR (PDR), clinically significant macular edema (CSME), diabe

48 r edema (DME), and 18 with proliferative DR (PDR)-and 64 age-matched nondiabetic control eyes.

49 ive DR (NPDR, N = 45), and proliferative DR (PDR, N = 35).

50 severe NPDR (n = 20), and proliferative DR (PDR; n = 72) were included.

51 oliferative DR [NPDR], 155 proliferative DR [PDR]) were analyzed; 302 (46.5%) were women and mean (SD

52 7.5% severe NPDR and 14.7% proliferative DR [PDR]) were reviewed.

53 rtion of participants with proliferative DR [PDR], clinically significant macular edema [CSME], or bo

54 onproliferative DR [NPDR], proliferative DR [PDR], or diabetic macular edema [DME]) or "any DR" (furt

55 ndomly assigned participants (1:1) to either PDR testing by oligonucleotide ligation assay (OLA) to g

56 tients with diabetic retinopathy, especially PDR, who are managed with anti-VEGF therapy alone, unint

57 indicated for PDR with DME in 7 (54%) eyes, PDR without DME in 3 (23%) eyes, and moderate to severe

58 sham control-treated subjects, time to first PDR event was significantly delayed in subjects treated

59 For PDR, sensitivity and specificity using 7-field ETDRS ima

60 eristics (HRC) group (80 eyes) and 3+/-1 for PDR in the group without HRC (10 eyes) (P < 0.001).

61 Adjustment for PDR did not alter HRs by race/ethnicity, but differences

62 The DRCR.net treatment algorithm for PDR can provide excellent clinical outcomes through 2 ye

63 retreatment protocol or PRP at baseline for PDR.

64 , 11.54-33.64, P < 0.0001) times greater for PDR than NPDR.

65 and ultra-widefield [UWF] fundus images for PDR) interpreted by trained nonmedical staff (ophthalmic

66 Anti-VEGF therapy was indicated for PDR with DME in 7 (54%) eyes, PDR without DME in 3 (23%)

67 ed ratio (1 point) and less than 10%/min for PDR (2 points).

68 ore accurate than in ICD-9, particularly for PDR compared with NPDR.

69 PRP), or (3) pars plana vitrectomy (PPV) for PDR; and study eye changes on the DRSS.

70 nd features of initial DR are prognostic for PDR development.

71 bizumab as an alternative therapy to PRP for PDR, at least through 2 years.

72 vitreous ranibizumab (0.5 mg) versus PRP for PDR.

73 ios of 0.5-mg ranibizumab therapy vs PRP for PDR.

74 o differences between treatment regimens for PDR were identified for most of the other patient-center

75 patients with a high clinical suspicion for PDR, wide-field SS OCTA likely will be the only imaging

76 Our finding that OLA testing for PDR reduced virological failure in only those with speci

77 anti-VEGF and PRP as first-line therapy for PDR, treatment decisions should be guided by considerati

78 endothelial growth factor (VEGF) therapy for PDR.

79 A high percentage of patients treated for PDR at the authors' institution were LTFU over a 4-year

80 P compared with IVR as primary treatment for PDR is less expensive over 2 years, but both fall well b

81 e of being LTFU, the choice of treatment for PDR must be considered carefully.

82 otocoagulation is an excellent treatment for PDR, people with diabetes in India need to be made aware

83 factor agents are proposed as treatments for PDR that spare peripheral vision.

84 93 participants (prevalence 9.4%) had PDR (95% CI 7.7-11.4).

85 Of these, 34 (5%) had PDR, and 702 (95%) had nonproliferative DR.

86 The high PDR prevalence may warrant resistance testing and/or alt

87 scular endothelial cells obtained from human PDR fibrovascular membranes (FVMs) via transcriptomic an

88 prove virological suppression by identifying PDR to guide drug selection for ART in a lower-middle in

89 y retinal nerve fiber layer was decreased in PDR (96 mum; 95% confidence interval [CI], 92-100 mum) v

90 regulation of VEGF and IL-18 was detected in PDR.

91 NV elsewhere in PDR was most prevalent superotemporally, and 99.4% of tr

92 and NPDR (P </= 0.03), while V was lower in PDR (P = 0.04).

93 Neovascularization in PDR can be identified at baseline and imaged serially af

94 research using WF SS-OCTA to identify NV in PDR, these findings suggest that WF SS-OCTA may be the o

95 f view was sufficient for detection of NV in PDR.

96 Retinal perfusion in PDR does not change significantly after PRP.

97 ng of the complex biologic effects of PRP in PDR.

98 RNP in PDR can be identified at baseline and imaged serially af

99 in-binding angiogenic factors upregulated in PDR vitreous humor besides VEGF, thus inhibiting their b

100 )/nucleoside reverse transcriptase inhibitor PDR vs no PDR was associated with longer time to VS (adj

101 or system as a viable tool for investigating PDR in a high-throughput fashion, but also uncover criti

102 measles-rubella vaccination campaign in Lao PDR to estimate the immunogenicity and vaccination cover

103 eported, continuing measles outbreaks in Lao PDR, and potentially elsewhere, may be attributable to s

104 iver Basin countries including Thailand, Lao PDR, Vietnam and Cambodia.

105 eyes with PDR, ranibizumab resulted in less PDR worsening compared with PRP, especially in eyes not

106 The very low PDR suggests poor access to diagnosis and care.

107 ved colonoscopy from physicians with a lower PDR.

108 the control healthy subjects, NPDR and mild PDR (p = 0.007).

109 % [high-risk PDR or worse] vs. 23% [moderate PDR or better]; HR, 3.97; 99% CI, 2.48 to 6.36; P < 0.00

110 as performed on 20 eyes with treatment-naive PDR from 15 patients.

111 as performed on 20 eyes with treatment-naive PDR from 15 patients.

112 Participants with treatment-naive PDR were imaged using the SS-OCTA 12- x 12-mm scan patte

113 NNRTI PDR would continue to increase if DTG-based ART was rest

114 arted on or switched to DTG-based ART, NNRTI PDR would reach 25.9% in 2040.

115 ucing DTG would lead to a reduction in NNRTI PDR in all scenarios if ART initiators are started on a

116 However, there was no impact of NNRTI PDR alone.

117 TG-based ART could reduce the level of NNRTI PDR from 52.4% (without DTG) to 10.4% (with universal DT

118 ly slow down the increase in levels of NNRTI PDR.

119 no difference between those with only NNRTI PDR vs no PDR (aHR, 1.05; 95% CI, 0.82-1.34) at the 5% t

120 ence between those with only NNRTI PDR vs no PDR (aHR, 1.05; 95% CI, 0.82-1.34) at the 5% threshold.

121 de reverse transcriptase inhibitor PDR vs no PDR was associated with longer time to VS (adjusted haza

122 ch scores, severe nonproliferative DR (NPDR)/PDR was independently associated with greater depressive

123 edications were less likely to develop NPDR, PDR, or DME and modest evidence that these patients are

124 , K or JT were associated with any DR, NPDR, PDR or DME.

125 g medications had a diagnosis code for NPDR, PDR, or DME or a procedural code for intravitreal inject

126 20 (55%), and 11 of 27 (41%) eyes with NPDR, PDR, and DME, respectively, demonstrated this feature (P

127 d year, 66 (59.5%) of NPDR and 28 (70.0%) of PDR eyes that manifested improvement at 1 year maintaine

128 We evaluated the ability of PDR to predict early mortality or retransplantation afte

129 The treatment coverage of PDR and CSME was 75% (56/75) in Indigenous Australians a

130 aocular delivery of FAc slows development of PDR and slows progression of diabetic retinopathy.

131 Time to first development of PDR was analyzed by Kaplan-Meier methods to calculate cu

132 th SS OCTA may facilitate early diagnosis of PDR.

133 tinal reperfusion with aflibercept dosing of PDR eyes with extensive RNP was not identified, and ther

134 le assembly checkpoint elevate expression of PDR-mediating efflux pumps in response to exposure to a

135 ration in serum was elevated in the group of PDR, and it was directly proportional to the level of th

136 We assessed the impact of PDR on virological suppression (VS; <50 copies/mL) in in

137 or that couples transcriptional induction of PDR genes to growth rate in the yeast Saccharomyces cere

138 the diagnosis and longitudinal management of PDR.

139 imaging modality for clinical management of PDR.

140 t and PRP can significantly reduce the NV of PDR patients and achieve better BCVA during the drug's l

141 this study, noteworthy was the percentage of PDR.

142 ed for 1148 individuals, and the presence of PDR was assessed at 5% and 20% detection thresholds.

143 NGS uncovered a high prevalence of PDR among participants enrolled in trial clinics in rura

144 Time to progression of PDR and VH were calculated with Cox regression after str

145 For these eyes, the rate of PDR-worsening was greater with PRP than ranibizumab (45%

146 IRMA increases risk of PDR whereas 4Q DBH increases risk of VH.

147 onal to the level of the clinical stadium of PDR, being significantly higher in the moderate and seve

148 O serum concentration and clinical stages of PDR, suggest that erythropoietin represents an important

149 igher in the moderate and severe subgroup of PDR comparing to the control healthy subjects, NPDR and

150 PV compared to 1-3 days for the treatment of PDR-related complications.

151 ors that contributed to delayed treatment of PDR.

152 prevalence estimates, and that the value of PDR testing to reduce virological failure should be asse

153 rs were invited to provide long-term data on PDR.

154 factors in N. crassa and characterized one (PDR-2) associated with pectin utilization and one with p

155 Patients with type 2 diabetes and DME or PDR have an increased risk of incident CVD, which sugges

156 Persons with DME or PDR were more likely to have incident CVD (IRR, 1.39; 95

157 .49-3.67) compared with those without DME or PDR.

158 ay for people with previously treated DME or PDR.

159 , 25.6%-71.5%) for those with severe NPDR or PDR (P = .02).

160 e in depressive symptoms, and severe NPDR or PDR contributed to 19.1% (95% CI, 1.7%-44.4%) of the tot

161 Those with severe NPDR or PDR did not have a statistically significant greater odd

162 roximately half of those with severe NPDR or PDR had difficulty with at least one visual function tas

163 ntly greater among those with severe NPDR or PDR relative to those with no retinopathy (adjusted odds

164 ntly greater among those with severe NPDR or PDR than among those with no retinopathy.

165 rgery compared with eyes with severe NPDR or PDR when controlling for baseline visual acuity (VA), wi

166 Severe NPDR or PDR, but not DME, was independently associated with depr

167 r "any DR" (further subclassified as NPDR or PDR, without or with DME).

168 etic macular edema (DME) with either NPDR or PDR.

169 eyes with stable treated PDR and persistent PDR at end of 10 year follow up, a significantly higher

170 Ninety eyes of 80 patients with persistent PDR (pPDR) despite adequate PRP were prospectively follo

171 system to genome-wide screens for potential PDR regulators.

172 easured by physicians' polyp detection rate (PDR).

173 w the calculation of patient diagnosis rate (PDR).

174 en clearance, the plasma disappearance rate (PDR), has been associated with initial graft function.

175 ucing the predictive, descriptive, relevant (PDR) framework for discussing interpretations.

176 ed testing for pretreatment drug resistance (PDR) before antiretroviral therapy (ART) initiation, the

177 d ART on NNRTI pretreatment drug resistance (PDR) in South Africa, 2020 to 2040.

178 re-antiretroviral-treatment drug resistance (PDR) is a predictor of human immunodeficiency virus (HIV

179 the impact of pretreatment drug resistance (PDR) on the efficacy of second generation integrase inhi

180 sporter family, pleiotropic drug resistance (PDR) transporters play essential functions, such as in h

181 ers that confer pleiotropic drug resistance (PDR).

182 he presence of pretreatment drug resistance (PDR).

183 drug-resistant (XDR) and pan-drug-resistant (PDR) Gram-negative pathogens.

184 strategy and projected distance resolution (PDR) method.

185 ssion to proliferative diabetic retinopathy (PDR) and the impact of FAc on changes in Early Treatment

186 veloping proliferative diabetic retinopathy (PDR) and vitreous hemorrhage (VH).

187 AMD) and proliferative diabetic retinopathy (PDR) are one of the major causes of blindness caused by

188 sed with proliferative diabetic retinopathy (PDR) be considered for pan-retinal photocoagulation (PRP

189 yes with proliferative diabetic retinopathy (PDR) following panretinal photocoagulation (PRP).

190 in 69%, proliferative diabetic retinopathy (PDR) in 31% and advanced diabetic eye disease (ADED) in

191 ted with proliferative diabetic retinopathy (PDR) in Caucasian patients with diabetes.

192 ening of proliferative diabetic retinopathy (PDR) in eyes treated with panretinal photocoagulation (P

193 ple with proliferative diabetic retinopathy (PDR) in India and highlight opportunities for improvemen

194 yes with proliferative diabetic retinopathy (PDR) in need of PRP were randomly assigned to 1 of 4 gro

195 Proliferative diabetic retinopathy (PDR) is a common cause of blindness in the developed wor

196 lmark of proliferative diabetic retinopathy (PDR) is retinal neovascularization.

197 PRP) for proliferative diabetic retinopathy (PDR) may lead to peripheral field loss that prevents dri

198 (NV) in proliferative diabetic retinopathy (PDR) on ultra-widefield (UWF) fluorescein angiography (F

199 rapy for proliferative diabetic retinopathy (PDR) or nonproliferative diabetic retinopathy (NPDR), wi

200 PDR) and proliferative diabetic retinopathy (PDR) were excellent (>90%).

201 16) and proliferative diabetic retinopathy (PDR) with tractional RD (n = 8).

202 eyes had proliferative diabetic retinopathy (PDR) without macular edema, and 27 eyes had diabetic mac

203 n (AMD), proliferative diabetic retinopathy (PDR), and proliferative vitreoretinopathy (PVR).

204 (NPDR), proliferative diabetic retinopathy (PDR), or diabetic macular edema (DME) and procedure code

205 tment of proliferative diabetic retinopathy (PDR), the leading cause of visual impairments in the wor

206 ase with proliferative diabetic retinopathy (PDR), vitrectomy was resorted for non clearing vitreous

207 managing proliferative diabetic retinopathy (PDR), with or without concomitant baseline diabetic macu

208 yes with proliferative diabetic retinopathy (PDR).

209 nt-naive proliferative diabetic retinopathy (PDR).

210 ndary to proliferative diabetic retinopathy (PDR).

211 f active proliferative diabetic retinopathy (PDR).

212 NPDR or proliferative diabetic retinopathy (PDR).

213 yes with proliferative diabetic retinopathy (PDR).

214 ssion of proliferative diabetic retinopathy (PDR).

215 tment of proliferative diabetic retinopathy (PDR).

216 d 30 had proliferative diabetic retinopathy (PDR).

217 PDR), and 38 with proliferative retinopathy (PDR) were imaged using spectral-domain optical coherence

218 DME] and proliferative diabetic retinopathy [PDR]) have a higher risk of CVD will allow physicians to

219 DME] and proliferative diabetic retinopathy [PDR]), which require frequent life-long follow-up, have

220 egardless of treatment group (64% [high-risk PDR or worse] vs. 23% [moderate PDR or better]; HR, 3.97

221 proliferative DR (PDR), 19.1%; and high-risk PDR, 4.4%; with PPL present in 61.8%.

222 For detection of high-risk PDR, sensitivity and specificity were higher when using

223 ological failure in only those with specific PDR mutations suggests that PDR poses less of a risk for

224 atients routinely imaged with a standardized PDR protocol between March 2017 and January 2019 were in

225 Venular V and Q were higher in NPDR than PDR subjects (P </= 0.04).

226 se with specific PDR mutations suggests that PDR poses less of a risk for virological failure than th

227 The PDR framework provides 3 overarching desiderata for eval

228 The PDR in 2011 was 0.34 (95% CI 0.25-0.44).

229 95% CI, 14.5-16.63 mm, respectively) and the PDR group (18.6 mm/mm(2); 95% CI, 14.9-22.30 mm/mm(2) an

230 er critical control mechanisms governing the PDR response and a previously uncharacterized link betwe

231 CI, 14.5-16.6 mm, respectively), and in the PDR versus the NPDR group.

232 Genes identified as down-regulators of the PDR included those encoding the MAD family of proteins i

233 To demonstrate how practitioners can use the PDR framework to evaluate and understand interpretations

234 proliferative diabetic retinopathy (NPDR) to PDR based on graded fundus photographs, (2) panretinal p

235 (P <= .05) higher in eyes that progressed to PDR compared with eyes that did not progress by 4 years.

236 ere compared between eyes that progressed to PDR in 4 years and eyes that did not progress.

237 Study eye progression to PDR based on a composite clinical outcome of (1) progres

238 Progression to PDR in 5 years differed by baseline DR: no DR (2.2%), mi

239 ifies new risk parameters for progression to PDR including the surface area of hemorrhages and the di

240 e showed greater reduction in progression to PDR with FAc treatment.

241 accurate means of predicting progression to PDR, and frequent monitoring of IRMAs with SS OCTA may f

242 he risk of DR progression and progression to PDR, especially with less severe DR at baseline.

243 ed with an increased risk for progression to PDR.

244 and January 2015 with a new VH secondary to PDR and treated with IVB were included.

245 management of patients with VH secondary to PDR.

246 ential role in select cases of laser-treated PDR with persistent NVs and no evidence of traction to a

247 On comparing eyes with stable treated PDR and persistent PDR at end of 10 year follow up, a si

248 Two PDR patients showed multiple NV and IRMA lesions at base

249 Patients with untreated PDR exhibited inner retinal dysfunction, as evidenced by

250 ith worsening DR severity (mild NPDR: 10% vs PDR: 31%, P = 0.007).

251 independent predictors of the endpoint were PDR (odds ratio [OR], 0.85; 95% confidence interval, 0.7

252 genous and Indigenous Australian adults with PDR or CSME have received laser treatment.

253 The study included 305 adults with PDR, the mean age was 52 years, 44% were women, and 52%

254 ninety-four study eyes from 305 adults with PDR, visual acuity (VA) 20/320 or better, and no history

255 follow-up at 55 US sites for 213 adults with PDR.

256 duration was the only factor associated with PDR.

257 Only age in females associated with PDR: A 5-year age decrease was associated with adjusted

258 ed in the group of people with diabetes with PDR.

259 s study examined 259 patients diagnosed with PDR and treated with PRP from 2015 to the present.

260 significantly decreased by 19% in eyes with PDR (0.020 +/- 0.005 mm(3), ss = -0.01, P = .01) compare

261 For 93 eyes with PDR at baseline, 1-year improvement rates were 75.9% for

262 A total of 651 eyes with PDR from 433 patients had at least 1 UWF FA with NV.

263 5) from 55.0 (IQR, 26.0-65.0), and eyes with PDR gained 15.0 letters (IQR, 6.0-29.5) from 55.0 (IQR,

264 Eyes with PDR that received only intravitreal anti-VEGF demonstrat

265 vant therapy, whereas 75.0% of the eyes with PDR with HRC responded.

266 In this study of eyes with PDR without DME, both monthly and quarterly aflibercept

267 9%) eyes with NPDR, 11 of 20 (55%) eyes with PDR, and 11 of 27 (41%) eyes with DME (P = .0001).

268 8%) eyes with NPDR, 13 of 20 (65%) eyes with PDR, and 17 of 27 (63%) eyes with DME (P = .007).

269 In eyes with PDR, ranibizumab resulted in less PDR worsening compared

270 Of the 46 participants with PDR and vision-impairing DME at baseline, 21 were assign

271 in the smaller subgroup of participants with PDR at baseline.

272 Among participants with PDR, virological failure was lower in the OLA-guided the

273 Untreated patients with PDR also had diffusely thinned RPE layers (P = 0.031) co

274 Forty eyes of 40 patients with PDR and no DME were enrolled in this study.

275 All patients with PDR and UWF FA imaging at the Bascom Palmer Eye Institut

276 mation was collected for 4,423 patients with PDR between April 30, 2012, and April 30, 2017.

277 th clinical appointments among patients with PDR is a substantial clinical challenge.

278 ar membranes (FVMs) taken from patients with PDR RUNX1 expression was increased in the vasculature, w

279 center included 43 laser-naive patients with PDR that required bilateral PRP.

280 elial growth factor therapy in patients with PDR who might otherwise receive laser treatment.

281 formed in a total of 418 adult patients with PDR who received IVI and/or PRP between January 1, 2014,

282 All patients with PDR without HRC responded to the adjuvant therapy, where

283 Among 4,423 patients with PDR, 2,407 (54.4%) and 2,320 (52.4%) were complete LTFU

284 Patients with PDR, retinopathy of prematurity (ROP), and wet age-relat

285 One hundred and fifty-six patients with PDR-related complications requiring PPV were prospective

286 sel formation in the retina of patients with PDR.

287 ing in the daily management of patients with PDR.

288 Evaluating the presenting VA of people with PDR, short-term outcomes at 6 months and the incidence o

289 n the United States for eyes presenting with PDR and vision-impairing DME, but not for those with PDR

290 e lower in the total cohort among those with PDR 65% (73/112) compared to those without PDR (85% [605

291 vision-impairing DME, but not for those with PDR without vision-impairing DME.

292 ach eye received a different treatment) with PDR, visual acuity 20/320 or better, no history of PRP.

293 In eyes without PDR (n = 109) at baseline, 56 (51%) had at least 1 field

294 After excluding patients without PDR or with insufficient image quality, 47 eyes of 35 pa

295 esults can be translated to patients without PDR.

296 h PDR 65% (73/112) compared to those without PDR (85% [605/713], P < 0.001), and for those on EFV-bas

297 t PRP also were at higher risk for worsening PDR (60% vs. 39%; HR, 2.04; 99% CI, 1.02 to 4.08; P = 0.

298 ars, the cumulative probability of worsening PDR was 42% (PRP) versus 34% (ranibizumab; hazard ratio

299 associated with increased risk of worsening PDR, regardless of treatment group (64% [high-risk PDR o

300 aracterized roles in the modulation of yeast PDR.